Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
Items 701–800 of 1,001
A Homogeneous Nonisotopic Histone Deacetylase Activity Assay
Heltweg, B., & Jung, M. (2003) · SLAS DISCOVERY · doi:10.1177/1087057102239644 · Cited by 37
“This has made them a promising class of new anticancer agents,(6,7) and first clinical studies are under way.(8) Therefore, assays for the measurement of HDAC activity or, respectively, its inhibition are useful tools both in mechanistical studies and in drug discovery.”
BackgroundNelson, B. N., & Friedman, J. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115951 · Cited by 41
“Butyrate is the preferred energy source for gut epithelial cells and can directly modulate genes by acting as histone deacetylases (HDACs) [172].”
BackgroundHalder, S. K., Cho, Y.-J., Datta, A., Anumanthan, G., Ham, A. L., Carbone, D. P., & Datta, P. K. (2011) · Neoplasia · doi:10.1593/neo.11576 · Cited by 36
“The cell cycle regulatory proteins p21, p16, and cyclins A and D are regulated by several HDAC inhibitors (HDIs) [10,11].”
BackgroundThe epigenetic basis for the aberrant expression of kallikreins in human cancers
Pampalakis, G., Diamandis, E. P., & Sotiropoulou, G. (2006) · Biological Chemistry · doi:10.1515/bc.2006.100 · Cited by 36
“In particular, the combination of histone deacetylase (HDAC) inhibitors with demethylating agents has become attractive, since histones are connected to DNA by both physical and functional interactions (Johnstone, 2002).”
BackgroundNovel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019)
He, X., Li, Z., Zhuo, X., Hui, Z., Xie, T., & Ye, X. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200217125419 · Cited by 36
Park, H., & Lee, S. (2004) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-004-2283-3 · Cited by 37
Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells
Nuutinen, T., Suuronen, T., Kyrylenko, S., Huuskonen, J., & Salminen, A. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.07.007 · Cited by 46
Chromatin, DNA methylation and neuron gene regulation — the purpose of the package
Sharma, R. P., Grayson, D. R., Guidotti, A., & Costa, E. (2005) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0535 · Cited by 39
Vinodhkumar, R., Song, Y., Ravikumar, V., Ramakrishnan, G., & Devaki, T. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.012 · Cited by 39
Kobayashi, H., Tan, E. M., & Fleming, S. E. (2004) · International Journal of Cancer · doi:10.1002/ijc.11697 · Cited by 37
Adeshakin, A. O., Yan, D., Zhang, M., Wang, L., Adeshakin, F. O., Liu, W., & Wan, X. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.155 · Cited by 40
The Versatility of Sirtuin-1 in Endocrinology and Immunology
Rasha, F. A., Mims, B. M., Castro‐Piedras, I., Barnes, B. J., Grisham, M. B., Rahman, R. L., & Pruitt, K. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.589016 · Cited by 36
“Currently, class I/II histone deacetylases are the targets of several molecule inhibitors in various phases of clinical trials, where some agents have yielded highly promising results (Johnstone, 2002; Rosato and Grant, 2004).”
BackgroundKim, Y. L., Lee, W., Chung, S. H., Yu, B. M., Lee, Y. C., & Hong, J. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121010 · Cited by 38
Parsana, N., Seoud, O. A. E., Al‐Ghamdi, A. A., Kasoju, N., & Malek, N. I. (2024) · ChemistrySelect · doi:10.1002/slct.202304157 · Cited by 35
Varghese, S., Gupta, D., Baran, T., Jiemjit, A., Gore, S. D., Casero, R. A., & Woster, P. M. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0505009 · Cited by 36
Lansigan, F., Choi, J., & Foss, F. M. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.07.014 · Cited by 38
Min, S. K., Koh, Y. H., Park, Y., Kim, H. J., Seo, J., Park, H., Cho, S. J., & Kim, I. S. (2012) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2012.46.2.142 · Cited by 35
“Age (yr)a 61 (15-96) 50 (25-81) 58 (32-92) Sex (M : F) 41 : 37 8 : 5 7 : 6 Follow-up (mo)a 31 (1-162) 18 (2-64) 15.”
Oxidative Stress, Thiol Redox Signaling Methods in Epigenetics
Sundar, I. K., Caito, S. W., Yao, H., & Rahman, I. (2010) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(10)74013-1 · Cited by 38
Design of small molecule epigenetic modulators
Pachaiyappan, B., & Woster, P. M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.001 · Cited by 35
Unravelling the Complexity and Functions of MTA Coregulators in Human Cancer
Li, D., & Kumar, R. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.005 · Cited by 37
Polyamine-based small molecule epigenetic modulators
Sharma, S. K., Hazeldine, S. T., Crowley, M. L., Hanson, A. S., Beattie, R. J., Varghese, S., Senanayake, T., Hirata, A., Hirata, F., Huang, Y., et al. (2012) · MedChemComm · doi:10.1039/c1md00220a · Cited by 37
Histone acetylation and its role in embryonic stem cell differentiation
Saraiva, N. Z., Oliveira, C. S., & Garcia, J. M. (2010) · World Journal of Stem Cells · doi:10.4252/wjsc.v2.i6.121 · Cited by 42
Kortenhorst, M. S. Q., Isharwal, S., van Diest, P. J., Chowdhury, W. H., Marlow, C., Carducci, M. A., Rodríguez, R., & Veltri, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1076 · Cited by 40
“Deregulation of the balance between histone acetyltransferases and histone deacetylase (HDAC) has been associated with oncogenesis in many tissues (2, 3).”
BackgroundBurgess, R. J., Jenkins, R. B., & Zhang, Z. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.9.6992 · Cited by 35
Xie, R., Yao, Y., Tang, P., Chen, G., Liu, X., Yun, F., Cheng, C., Wu, X., & Yuan, Q. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.038 · Cited by 34
Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption
Onyia, J. E., Galvin, R. J. S., Li, Y., Halladay, D., Miles, R. R., Yang, X., Fuson, T. R., Cain, R. L., Zeng, Q. Q., Chandrasekhar, S., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057893 · Cited by 37
“HDAC inhibitors are being evaluated for treatment of cancer (Johnstone, 2002).”
BackgroundWu, Y., Ou, C., Chien, P., Chang, H. H., Ko, J., & Wang, B. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.218 · Cited by 33
Quantifying Tip60 (Kat5) stratifies breast cancer
McGuire, A., Casey, M., Shalaby, A., Kalinina, O., Curran, C. E., Webber, M., Callagy, G. M., Holian, E., Bourke, E., Kerin, M. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40221-5 · Cited by 34
Varizhuk, A. M., Isaakova, E. A., & Pozmogova, G. E. (2019) · BioEssays · doi:10.1002/bies.201900091 · Cited by 38
Singh, S. V., Chaube, B., Mayengbam, S. S., Singh, A., Malvi, P., Mohammad, N., Deb, A., & Bhat, M. K. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166011 · Cited by 39
Saettone, V., Biasato, I., Radice, E., Schiavone, A., Bergero, D., & Meineri, G. (2020) · Animals · doi:10.3390/ani10122199 · Cited by 39
Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy
Conte, M., Fontana, E., Nebbioso, A., & Altucci, L. (2020) · Marine Drugs · doi:10.3390/md19010015 · Cited by 39
“Panobinostat treatment also showed effective HDAC inhibition in breast, prostate, colon, and pancreatic cancer cell lines, while its effects on normal cells were marginal [55,56], suggesting its cancer-specific selectivity.”
BackgroundThe Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer
Colonne, C. K., Favaloro, E. J., & Pasalic, L. (2022) · Healthcare · doi:10.3390/healthcare10030557 · Cited by 33
Myeloid-derived suppressor cell: A crucial player in autoimmune diseases
Xu, D., Li, C., Xu, Y., Huang, M., Cui, D., & Xie, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1021612 · Cited by 35
Nielsen, T. K., Hildmann, C., Riester, D., Wegener, D., Schwienhorst, A., & Ficner, R. (2007) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309107012377 · Cited by 36
Virtual screening and experimental validation of novel histone deacetylase inhibitors
Huang, Y., Zhao, J., Song, Q., Zheng, L., Fan, C., Liu, T., Bao, Y., Sun, L., Zhang, L., & Li, Y. (2016) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-016-0075-8 · Cited by 35
“HDAC inhibitors have emerged as a new class of therapeutic agents and have generated much interest among pharmacologists, and cancer and diabetes researchers [5, 12, 13].”
BackgroundExploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors
Shadrick, W. R., Slavish, P. J., Chai, S. C., Waddell, M. B., Connelly, M., Low, J. A., Tallant, C., Young, B. M., Bharatham, N., Knapp, S., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.042 · Cited by 35
“Isopropyl (E)-but-2-enoylcarbamate (5)—To a solution of isopropyl carbamate (15.”
Functionalized Graphene Oxide Thin Films for Anti-tumor Drug Delivery to Melanoma Cells
Sima, L. E., Chirițoiu, G. N., Neguț, I., Grumezescu, V., Orobeti, S., Munteanu, C. V. A., Sima, F., & Axente, E. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00184 · Cited by 34
“HDAC inhibitors are a promising class of compounds that showed low side effects while constituting an alternative treatment for hematological as well as solid malignancies (Johnstone, 2002; Kelly and Marks, 2005).”
BackgroundHistone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells
Jiang, S., Dowdy, S. C., Meng, X. W., Wang, Z., Jones, M. B., Podratz, K. C., & Jiang, S. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.012 · Cited by 33
Varghese, S., Senanayake, T., Stewart, T. M., Doering, K., Fraser, A. V., Casero, R. A., & Woster, P. M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701384x · Cited by 34
Kim, H. M., Lee, K., Park, B. W., Ryu, D. K., Kim, K., Lee, C. W., Park, S., Han, J. W., Lee, H. Y., Lee, H. Y., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.091 · Cited by 34
A steered molecular dynamics mediated hit discovery for histone deacetylases
Kalyaanamoorthy, S., & Chen, Y. P. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp53511h · Cited by 32
Sharma, S., Beck, J., Mita, M. M., Paul, S., Woo, M. M., Squier, M. K. T., Gadbaw, B., & Prince, H. M. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9930-2 · Cited by 32
“[9] Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.”
BackgroundLanuti, P., Bertagnolo, V., Pierdomenico, L., Bascelli, A., Santavenere, E., Alinari, L., Capitani, S., Miscia, S., & Marchisio, M. (2009) · Cell Research · doi:10.1038/cr.2009.80 · Cited by 32
A novel two-step QSAR modeling work flow to predict selectivity and activity of HDAC inhibitors
Zhao, L., Xiang, Y., Song, J., & Zhang, Z. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.12.067 · Cited by 33
Venturelli, S., Niessner, H., Sinnberg, T. W., Berger, A., Burkard, M., Urmann, C., Donaubauer, K., Böcker, A., Leischner, C., Riepl, H., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495275 · Cited by 32
Propionate promotes intestinal lipolysis and metabolic benefits via AMPK/LSD1 pathway in mice
Wang, D., Liu, C.-D., Tian, M.-L., Tan, C., Shu, G., Jiang, Q., Zhang, L., & Yin, Y. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0188 · Cited by 33
“Meanwhile, propionate also acts as a modulator of epigenome by altering histone acetylation (Johnstone 2002).”
BackgroundReda, M. M., Bagley, A. F., Zaidan, H. Y., & Yantasee, W. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.06.041 · Cited by 39
“Moreover, inhibiting HDAC relaxes chromatin and can result in more DNA damage following IR [47,48].”
BackgroundHDAC3i‐Finder: A Machine Learning‐based Computational Tool to Screen for HDAC3 Inhibitors
Li, S., Ding, Y., Chen, M., Chen, Y., Kirchmair, J., Zhu, Z., Wu, S., & Xia, J. (2020) · Molecular Informatics · doi:10.1002/minf.202000105 · Cited by 33
Lee, K. H., Choi, E. Y., Kim, M. K., Kim, K. O., Jang, B. I., Kim, S. W., Kim, S. W., Song, S. K., & Kim, J. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0510-x · Cited by 32
“Based on these activities, HDAC inhibitors have exhibited anti-tumor effects in clinical trials [14, 15].”
BackgroundInhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation
He, G., Wang, Y., Pang, X., & Zhang, B. (2013) · Tumor Biology · doi:10.1007/s13277-013-1134-z · Cited by 37
“Since HDACi can reverse the epigenetic silencing that is frequently observed in cancer, this has led to the development of various HDAC inhibitors for cancer therapy [7–10].”
Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group
Li, Y., & Woster, P. M. (2015) · MedChemComm · doi:10.1039/c4md00401a · Cited by 33
Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk
Wang, J. R., Gramling, S. J. B., Goldstein, D. P., Cheng, D., Chen, D., Azad, A. K., Tse, A., Hon, H., Chen, Z., Mirshams, M., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt008 · Cited by 32
Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes
Hara, N., Alkanani, A. K., Dinarello, C. A., & Zipris, D. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1078-1 · Cited by 35
“Histone deacetylases (HDACs) are a class of enzymes that remove acetyl groups from histone, allowing histone molecules to wrap the DNA more tightly (reviewed in reference [4]).”
BackgroundHistone Deacetylase Inhibitors: Updated Studies in Various Epigenetic-Related Diseases
Zwergel, C., Stazi, G., Valente, S., & Mai, A. (2016) · Journal of Clinical Epigenetics · Cited by 43
Verma, M., Dunn, B. K., Ross, S. A., JAIN, P., Wang, W., Hayes, R. B., & Umar, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb05984.x · Cited by 34
Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates
Berg, S. L., Stone, J., Xiao, J. J., Chan, K. K., Nuchtern, J. G., Dauser, R., McGuffey, L., Thompson, P., & Blaney, S. M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0766-5 · Cited by 34
“Abnormalities of histone acetylation are associated with the malignant phenotype [1, 2, 3, 4, 5, 6].”
BackgroundJohnson, J., Pahuja, A., Graham, M. L., Hering, B. J., Hancock, W. W., & Bansal‐Pakala, P. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.01.039 · Cited by 32
Natural Products as Zinc‐Dependent Histone Deacetylase Inhibitors
Tan, S., & Liu, Z. (2015) · ChemMedChem · doi:10.1002/cmdc.201402460 · Cited by 35
Inoue, S., Harper, N., Walewska, R. J., Dyer, M. J. S., & Cohen, G. M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0451 · Cited by 33
Huong, T. L., Dung, D. T. M., Huan, N.-V., Cuong, L.-V., Pham‐The, H., Le‐Thi‐Thu, H., Kim, J., Kim, Y.-G., Han, S., & Nam, N. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.02.002 · Cited by 32
Renoir, J. (2012) · Steroids · doi:10.1016/j.steroids.2012.07.019 · Cited by 33
Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors
Baud, M. G. J., Leiser, T., Petrucci, V., Gunaratnam, M., Neidle, S., Meyer‐Almes, F., & Fuchter, M. J. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.11 · Cited by 34
Kim (2009) · International Journal of Oncology · doi:10.3892/ijo_00000483 · Cited by 31
Enhancing the anti-angiogenic action of histone deacetylase inhibitors
Kuljaca, S., Liu, T., Tee, A. E., Haber, M., Norris, M. D., Dwarte, T. M., & Marshall, G. M. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-68 · Cited by 36
“induce cancer cell differentiation, growth arrest, programmed cell death, and inhibit tumour-driven angiogenesis [1,3].”
BackgroundWang, X., Jackson, L. N., Johnson, S. M., Wang, Q., & Evers, B. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1080 · Cited by 32
“A number of HDACi, such as vorinostat, belinostat, entinostat, and valproic acid, have or are presently being evaluated in clinical trials for the treatment of various cancers, including colorectal cancer (16, 18, 21).”
BackgroundXu, J., Sun, J., Wang, P., Ma, X., & Li, S. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1419355 · Cited by 31
Efficient Solid-Phase Synthesis of FK228 Analogues as Potent Antitumoral Agents
Maro, S. D., Pong, R.-C., Hsieh, J., & Ahn, J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800959f · Cited by 31
Siddiqi, T., Frankel, P., Beumer, J. H., Kiesel, B. F., Christner, S., Ruel, C., Song, J. Y., Chen, R., Kelly, K. R., Ailawadhi, S., et al. (2020) · Leukemia & Lymphoma · doi:10.1080/10428194.2019.1672052 · Cited by 30
“HDAC inhibitors are a class of anti-cancer agents acting on chromatin structure and function [32].”
BackgroundXie, R., Li, Y., Tang, P., & Yuan, Q. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.011 · Cited by 30
Igaz, N., Szöke, K., Kovács, D., Buhala, A., Varga, Z., Bélteky, P., Rázga, Z., Tiszlavicz, L., Vízler, C., Hidéghety, K., et al. (2020) · Nanomaterials · doi:10.3390/nano10010158 · Cited by 34
“This fairly relaxed, open chromatin structure is highly accessible to transcription factors and enables active gene expression, albeit rendering the DNA more susceptible to various damaging factors [49,71].”
BackgroundWang, Y., Shao, S., Guo, C., Zhang, S., Li, M., & Ding, K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.05.009 · Cited by 30
The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities
Psilopatis, I., Vrettou, K., Fleckenstein, F. N., & Theocharis, S. E. (2023) · Cells · doi:10.3390/cells12091227 · Cited by 36
Hanessian, S., Auzzas, L., Giannini, G., Marzi, M., Cabri, W., Barbarino, M., Vesci, L., & Pisano, C. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.014 · Cited by 38
Sule, N., Singh, P., & Srivastava, D. K. (2008) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2008.011 · Cited by 30
Williams, R. M. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo2003693 · Cited by 30
Lim, B., Murthy, R. K., Lee, J., Jackson, S. A., Iwase, T., Davis, D. W., Willey, J. S., Wu, J., Shen, Y., Tripathy, D., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0473-y · Cited by 31
Matsuoka, H., Fujimura, T., Hayashi, M., Matsuda, K., Ishii, Y., Aramori, I., & Mutoh, S. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.05.002 · Cited by 32
Kanzaki, M., Kakinuma, H., Kumazawa, T., Inoue, T., Saito, M., Narita, S., Yuasa, T., Tsuchiya, N., & Habuchi, T. (2007) · Oncology Reports · doi:10.3892/or.17.4.761 · Cited by 30
Kaler, P., Sasazuki, T., Shirasawa, S., Augenlicht, L. H., & Klampfer, L. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.01.010 · Cited by 34
Zhang, L., & Freitas, M. A. (2004) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2004.02.012 · Cited by 31
Balliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31
RetractedBaud, M. G. J., Leiser, T., Meyer‐Almes, F., & Fuchter, M. J. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00824a · Cited by 32
Satwani, P., Bavishi, S., Saha, A., Zhao, F., Ayello, J. S., van de Ven, C., Chu, Y., & Cairo, M. S. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.008 · Cited by 30
Trichostatin A Protects Liver against Septic Injury through Inhibiting Toll-Like Receptor Signaling
Kim, S.-J., Park, J.-S., Lee, D.-W., & Lee, S.-M. (2016) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.176 · Cited by 30
“HDAC catalyzes the hydrolytic removal of the acetyl group of histone resulting in chromatin condensation and transcriptional silencing (Johnstone, 2002).”
BackgroundPerona, M., Thomasz, L., Rossich, L. E., Rodriguez, C., Pisarev, M. A., Rosemblit, C., Cremaschi, G., Dagrosa, M. A., & Juvenal, G. J. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.08.007 · Cited by 29
Elek, G. Z., Koppel, K., Zubrytski, D. M., Konrad, N., Järving, I., Lopp, M., & Kananovich, D. G. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b03305 · Cited by 32
Pal, D., Raj, K., Nandi, S. S., Sinha, S., Mishra, A., Mondal, A., Lagoa, R., Burcher, J. T., & Bishayee, A. (2023) · Cancers · doi:10.3390/cancers15102808 · Cited by 32
Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers
Fang, J. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03807.x · Cited by 32
Drosophila Histone Deacetylase-3 Controls Imaginal Disc Size through Suppression of Apoptosis
Zhu, C. C., Bornemann, D. J., Zhitomirsky, D., Miller, E., O’Connor, M. B., & Simon, J. A. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000009 · Cited by 30
“show potential as anticancer agents in preclinical studies with cell and animal models [48,49].”
BackgroundDNA methylation changes in a human cell model of breast cancer progression
Fernandez, S. V., Snider, K. E., Wu, Y.-Z., Russo, I. H., Plass, C., & Russo, J. (2010) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2010.02.007 · Cited by 31
“Another chemical agent commonly used to modulate the expression of silenced genes in cancer cells is the histone deacetylase inhibitor trichostatin (TSA) [14,15].”
Synthesis and anticancer activities of thieno[3,2-d]pyrimidines as novel HDAC inhibitors
Tan, Q., Zhang, Z., Jie, H., Zhao, Y. C., & Zhu, L. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.11.021 · Cited by 29
Molecular Targets in the Treatment of Cardiac Hypertrophy
Kühn, C., Hille, S. S., & Frey, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_18 · Cited by 29
Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy
Eom, G. H., & Kook, H. Y. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.3.242 · Cited by 29
“arrests the cell cycle or induces apoptosis (26).”
BackgroundHymes, K. B. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.014 · Cited by 36
Modesitt, S. C., & Parsons, S. J. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.06.030 · Cited by 31
“HDAC inhibitors have been identified as potential anti-neoplastic agents [4–10].”
BackgroundPellicciotta, I., Cortez‐Gonzalez, X., Šášik, R., Reiter, Y., Hardiman, G., Langlade‐Demoyen, P., & Zanetti, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1014 · Cited by 31
“Although HDAC inhibitors alter 2% to 5% of the genome depending on the cell type and the inhibitor (22, 29), we could identify transcriptional changes that directly relate to the MHC I”
Molecular therapeutic approaches to melanoma
Ji, Z., Flaherty, K. T., & Tsao, H. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.004 · Cited by 34
Gene Expression Profiling of Breast Cancers with Emphasis of β-Catenin Regulation
Roh, M. S., Hong, S. H., Jeong, J. S., Kwon, H. C., Kim, M. C., Cho, S. H., Yoon, J. H., & Hwang, T. H. (2004) · Journal of Korean Medical Science · doi:10.3346/jkms.2004.19.2.275 · Cited by 30
“On the other hand, the HAT directly links chromatin modifica- tion to genetic activation and has also important activities in many cellular processes including cell cycle progression, transcription and DNA replication (17).”
BackgroundResultInfluentialVolume-sensitive Cl(-) channel as a regulator of acquired cisplatin resistance.
Shimizu, T., Lee, E. L., Ise, T., & Okada, Y. (2008) · PubMed · Cited by 37
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.